Targeting of FBN1 or the fibrillin-1 protein may provide a therapeutic avenue for conditions where there is a deficiency of adipose tissue (such as Marfan syndrome and lipodystrophy) and for obesity and type II diabetes, responsible for a major health burden in today's world. This evidence concerns the gene FBN1 and obesity disorder.